P53.01 Clinical Application of NGS Technology. Therapeutic Possibilities and Future Perspectives

2021 ◽  
Vol 16 (10) ◽  
pp. S1124-S1125
Author(s):  
S. Sequero-Lopez ◽  
A. Segura ◽  
I. García-Pérez ◽  
L. Gálvez-Carvajal ◽  
D. Castillo-Barnes ◽  
...  
Keyword(s):  
Clinical Application ◽  
Future Perspectives ◽  
Therapeutic Possibilities

scholarly journals The Complexity of FGF23 Effects on Cardiomyocytes in Normal and Uremic Milieu

Cells ◽  
2021 ◽  
Vol 10 (5) ◽  
pp. 1266
Author(s):  
Andreja Figurek ◽  
Merita Rroji ◽  
Goce Spasovski
Keyword(s):  
Chronic Kidney Disease ◽  
Heart Disease ◽  
Cardiovascular Risk ◽  
Current Knowledge ◽  
Fibroblast Growth Factor 23 ◽  
Mechanisms Of Action ◽  
Fibroblast Growth ◽  
Normal Kidney ◽  
Future Perspectives ◽  
Therapeutic Possibilities

Fibroblast growth factor-23 (FGF23) appears to be one of the most promising biomarkers and predictors of cardiovascular risk in patients with heart disease and normal kidney function, but moreover in those with chronic kidney disease (CKD). This review summarizes the current knowledge of FGF23 mechanisms of action in the myocardium in the physiological and pathophysiological state of CKD, as well as its cross-talk to other important signaling pathways in cardiomyocytes. In this regard, current therapeutic possibilities and future perspectives are also discussed.

scholarly journals VEGF in nuclear medicine: Clinical application in cancer and future perspectives (Review)

2016 ◽  
Vol 49 (2) ◽  
pp. 437-447 ◽  
Author(s):  
Samanta Taurone ◽  
Filippo Galli ◽  
Alberto Signore ◽  
Enzo Agostinelli ◽  
Rudi A.J.O. Dierckx ◽  
...  
Keyword(s):  
Nuclear Medicine ◽  
Clinical Application ◽  
Future Perspectives

scholarly journals NEW IMMUNOLOGICAL CHECKPOINTS FOR CANCER IMMUNOTHERAPY

2017 ◽  
Vol 22 (4) ◽  
pp. 175-179
Author(s):  
Andrei I. Chapoval ◽  
S. V Podlesnykh ◽  
E. A Kolosova ◽  
D. N Shcherbakov
Keyword(s):  
Immune Response ◽  
T Cell ◽  
Cancer Patient ◽  
Cancer Immunotherapy ◽  
Cancer Patients ◽  
Clinical Application ◽  
Cell Mediated Immune Response ◽  
B7 Family ◽  
Therapeutic Possibilities

Members of B7-CD28 family ligands and receptors play the important role in the co-stimulation and inhibition of the T-cell mediated immune response. Blocking of the B7 family molecules inhibiting the immune response (also called immunological checkpoints), CTLA4 and PD-1 / PD-L1 promoted to important therapeutic achievements in cancer immunotherapy and improved survival of cancer patient. The recent discovery of new B7 family molecules (such as B7-H3 [CD276], B7-H4 [B7S1 / B7x / Vtcn1], B7-H5 [VISTA / PD-1H / GI24], B7-H6 and B7-H7 [HHLA2]) has expanded therapeutic possibilities for the management of cancer patients. In this article, we discuss the clinical application of known blockers of immunological checkpoints and the prospects for the use of newly discovered molecules.

scholarly journals Circulating free tumor DNA in non-small cell lung cancer (NSCLC): clinical application and future perspectives

2019 ◽  
Vol 11 (S1) ◽  
pp. S113-S126 ◽  
Author(s):  
Guillaume Herbreteau ◽  
Audrey Vallée ◽  
Sandrine Charpentier ◽  
Nicola Normanno ◽  
Paul Hofman ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Clinical Application ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Future Perspectives ◽  
Small Cell Lung ◽  
Tumor Dna

scholarly journals The regulation of nanomaterials and nanomedicines for clinical application: current and future perspectives

2020 ◽  
Vol 8 (17) ◽  
pp. 4653-4664 ◽  
Author(s):  
Rachel Foulkes ◽  
Ernest Man ◽  
Jasmine Thind ◽  
Suet Yeung ◽  
Abigail Joy ◽  
...  
Keyword(s):  
Clinical Application ◽  
Clinical Translation ◽  
Future Perspectives ◽  
Regulatory Factors ◽  
The Past

Nanomedicine research has increased drastically over the past ten years, however, before clinical translation many regulatory factors must be considered.

scholarly journals Promoting reactive oxygen species generation: a key strategy in nanosensitizer-mediated radiotherapy

Nanomedicine ◽  
2021 ◽  
Author(s):  
Shichong Jia ◽  
Shengfang Ge ◽  
Xianqun Fan ◽  
Kam W Leong ◽  
Jing Ruan
Keyword(s):  
Reactive Oxygen Species ◽  
Cancer Patients ◽  
Clinical Application ◽  
Reactive Oxygen Species Generation ◽  
Reactive Oxygen ◽  
Ros Generation ◽  
Enhancement Effect ◽  
Oxygen Species ◽  
Future Perspectives

The radiotherapy enhancement effect of numerous nanosensitizers is based on the excessive production of reactive oxygen species (ROS), and only a few systematic reviews have focused on the key strategy in nanosensitizer-mediated radiotherapy. To clarify the mechanism underlying this effect, it is necessary to understand the role of ROS in radiosensitization before clinical application. Thus, the source of ROS and their principle of tumor inhibition are first introduced. Then, nanomaterial-mediated ROS generation in radiotherapy is reviewed. The double-edged sword effect of ROS and the potential dangers they may pose to cancer patients are subsequently addressed. Finally, future perspectives regarding ROS-regulated nanosensitizer applications and development are discussed.

Sign in / Sign up

Export Citation Format

Share Document